CTLA4 and neoplasm: Efficacy patterns from single-agent anti-CTLA4 therapy, including concerns about the confounding effects of pseudoprogression, led to recommendations to delay initial radiographic assessment and/or consider relatively minor tumor growth not to represent treatment failure, as captured in immune-related response RECIST guidelines (49).